Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of GLPG2222 in adults with cystic fibrosis homozygous for F508del
NL-OMON45460Phase 2Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galicaftor in cystic fibrosis (CF) (6 arms), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability. Started May 2017; status: active, not recruiting.
02
Drugs
galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45460.